Precision targeting of mTOR in conventional and MHC class I-restricted anti-tumour CD4+ T cells

传统和 MHC I 类限制性抗肿瘤 CD4 T 细胞中 mTOR 的精确靶向

• 批准号: MR/P019072/1
• 负责人: Francesca Sillito
• 金额: $ 43.07万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FP019072%2F1
• 关键词: Precision; targeting; mTOR; conventional; MHC

Adoptive immunotherapy is an emerging therapy that has provided exciting preliminary results in some cancer patients. The protocols involve removing immune cells called T cells from patients and then reprogramming them to attack cancer cells. However, early results show that not all patients will respond to the treatment or will later relapse, meaning either that the T cells don't work or that the cancer changes and evades the immune attack. In our laboratory, we are developing methods to broaden the immune attack by including other immune cells. In this project, we will evaluate how modifying a subset of immune cells called CD4+ T cells can improve their ability to target cancer cells following infusion and then, keep working to ensure that the cancer cannot regrow. We intend to use this knowledge to design new approaches for adoptive immunotherapy in patients.

免疫疗法是一种新兴的治疗方法，在一些癌症患者中提供了令人兴奋的初步结果。该方案涉及从患者体内去除称为T细胞的免疫细胞，然后重新编程它们以攻击癌细胞。然而，早期的结果表明，并非所有患者都会对治疗产生反应或随后复发，这意味着T细胞不起作用或癌症发生变化并逃避免疫攻击。在我们的实验室中，我们正在开发通过包括其他免疫细胞来扩大免疫攻击的方法。在这个项目中，我们将评估如何修饰一个称为CD4+ T细胞的免疫细胞亚群，以提高它们在输注后靶向癌细胞的能力，然后继续努力确保癌症不能再生。我们打算利用这些知识来设计新的方法，用于患者的过继免疫治疗。

项目成果

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

一项评估同种异体限制性 WT1-TCR 基因修饰自体 T 细胞在不适合同种异体干细胞移植的高危骨髓恶性肿瘤患者中的安全性和持久性的 I 期研究

• DOI: 10.1182/blood-2019-128044
• 发表时间: 2019
• 期刊: Blood
• 影响因子: 20.3
• 作者: Morris E